PDF(Pubmed)
Abstract：
UNASSIGNED: Detailed clinical information regarding drug-induced constipation (DIC) is limited. This study aimed to investigate the real-world situation of DIC.
UNASSIGNED: This retrospective study used data from a Japanese claims database registered from 2014 to 2021. The constipation cohort included subjects with at least one record of treated constipation, while the non-constipation cohort was selected through random stratified sampling method, to match the constipation cohort by gender. The study population and control with at least one history of a known causative drug (CD) were matched 1:1 using propensity scores. The proportion of potential DIC (pDIC), the timing of diagnosis for pDIC, and the proportion of prescriptions by drug class for both the CDs and the laxatives were calculated, while logistic regression analysis was performed to explore additional associated factors.
UNASSIGNED: Of the 4 533 905 subjects, 178 852 were eligible in both the study population and the control. The pDIC group comprised of 19 485 patients, which accounted for 10.9% of all treated constipation subjects, while the non-constipation with CD group had 10 430 subjects. The median duration between the recorded CD prescription and treated constipation was 38.0 days. The most frequently prescribed CD was cardiovascular drugs (47.9%). All CD classes, being male, and some comorbidities were associated with the occurrence of pDIC.
UNASSIGNED: The pDIC subjects accounted for about 11% of all treated constipation cases. Since DIC requires different treatment regimens compared to other constipation types, physicians should be cognizant to provide patients with optimized treatments.
UNASSIGNED: This retrospective study used data from a Japanese claims database registered from 2014 to 2021. The constipation cohort included subjects with at least one record of treated constipation, while the non-constipation cohort was selected through random stratified sampling method, to match the constipation cohort by gender. The study population and control with at least one history of a known causative drug (CD) were matched 1:1 using propensity scores. The proportion of potential DIC (pDIC), the timing of diagnosis for pDIC, and the proportion of prescriptions by drug class for both the CDs and the laxatives were calculated, while logistic regression analysis was performed to explore additional associated factors.
UNASSIGNED: Of the 4 533 905 subjects, 178 852 were eligible in both the study population and the control. The pDIC group comprised of 19 485 patients, which accounted for 10.9% of all treated constipation subjects, while the non-constipation with CD group had 10 430 subjects. The median duration between the recorded CD prescription and treated constipation was 38.0 days. The most frequently prescribed CD was cardiovascular drugs (47.9%). All CD classes, being male, and some comorbidities were associated with the occurrence of pDIC.
UNASSIGNED: The pDIC subjects accounted for about 11% of all treated constipation cases. Since DIC requires different treatment regimens compared to other constipation types, physicians should be cognizant to provide patients with optimized treatments.
摘要：
■关于药物引起的便秘（DIC）的详细临床信息有限。本研究旨在调查DIC的实际情况。
■这项回顾性研究使用了2014年至2021年注册的日本索赔数据库的数据。便秘队列包括至少有一个治疗便秘记录的受试者，而非便秘队列是通过随机分层抽样方法选择的，按性别匹配便秘队列。使用倾向评分将具有至少一个已知致病药物（CD）病史的研究人群和对照进行1：1匹配。潜在DIC（PDIC）的比例，PDIC的诊断时机,计算了CD和泻药按药物类别划分的处方比例，同时进行logistic回归分析以探讨其他相关因素.
■在4533905个科目中，178852在研究人群和对照中均合格。pDIC组包括19485名患者，占所有治疗便秘受试者的10.9%，而非便秘型CD组有10430名受试者。记录的CD处方和治疗的便秘之间的中位持续时间为38.0天。最常用的CD是心血管药物（47.9％）。所有CD类，作为男性，一些合并症与pDIC的发生有关。
■pDIC受试者占所有治疗便秘病例的约11%。由于与其他便秘类型相比，DIC需要不同的治疗方案，医生应该认识到为患者提供优化的治疗方法。
■这项回顾性研究使用了2014年至2021年注册的日本索赔数据库的数据。便秘队列包括至少有一个治疗便秘记录的受试者，而非便秘队列是通过随机分层抽样方法选择的，按性别匹配便秘队列。使用倾向评分将具有至少一个已知致病药物（CD）病史的研究人群和对照进行1：1匹配。潜在DIC（PDIC）的比例，PDIC的诊断时机,计算了CD和泻药按药物类别划分的处方比例，同时进行logistic回归分析以探讨其他相关因素.
■在4533905个科目中，178852在研究人群和对照中均合格。pDIC组包括19485名患者，占所有治疗便秘受试者的10.9%，而非便秘型CD组有10430名受试者。记录的CD处方和治疗的便秘之间的中位持续时间为38.0天。最常用的CD是心血管药物（47.9％）。所有CD类，作为男性，一些合并症与pDIC的发生有关。
■pDIC受试者占所有治疗便秘病例的约11%。由于与其他便秘类型相比，DIC需要不同的治疗方案，医生应该认识到为患者提供优化的治疗方法。
